Search research articles
Contact Us
Filters
Showing results (221-230 of 426) with videos related to
Page
of 43
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 1, 2004
ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas
Johann S de Bono, Anthony W Tolcher, Andre Forero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2015
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer
Howard I Scher, Glenn Heller, Arturo Molina, et al.
Oncogene
|
July 20, 2007
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
G Attard, J Clark, L Ambroisine, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 31, 2012
Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer
Alison H M Reid, Gerhardt Attard, Daniel Brewer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2011
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors
Simon Pacey, Richard H Wilson, Mike Walton, et al.
Science Translational Medicine
|
September 19, 2014
Tumor clone dynamics in lethal prostate cancer
Suzanne Carreira, Alessandro Romanel, Jane Goodall, et al.
Cancer Research
|
October 9, 2021
Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer
Amy C Mandigo, Ayesha A Shafi, Jennifer J McCann, et al.
The Lancet. Oncology
|
April 19, 2015
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Yohann Loriot, Kurt Miller, Cora N Sternberg, et al.
Cancer Chemotherapy and Pharmacology
|
June 1, 2006
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma
Monica M Mita, Eric K Rowinsky, Leonardo Forero, et al.
The Lancet. Oncology
|
May 29, 2025
Health-related quality of life, pain, and symptomatic skeletal events with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
Karim Fizazi, Michael J Morris, Neal D Shore, et al.
Page
of 43
Search research articles
Search
Showing results (221-230 of 426) with videos related to
Sort By:
Page
of 43
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 1, 2004
ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas
Johann S de Bono, Anthony W Tolcher, Andre Forero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2015
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer
Howard I Scher, Glenn Heller, Arturo Molina, et al.
Oncogene
|
July 20, 2007
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
G Attard, J Clark, L Ambroisine, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 31, 2012
Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer
Alison H M Reid, Gerhardt Attard, Daniel Brewer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2011
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors
Simon Pacey, Richard H Wilson, Mike Walton, et al.
Science Translational Medicine
|
September 19, 2014
Tumor clone dynamics in lethal prostate cancer
Suzanne Carreira, Alessandro Romanel, Jane Goodall, et al.
Cancer Research
|
October 9, 2021
Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer
Amy C Mandigo, Ayesha A Shafi, Jennifer J McCann, et al.
The Lancet. Oncology
|
April 19, 2015
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Yohann Loriot, Kurt Miller, Cora N Sternberg, et al.
Cancer Chemotherapy and Pharmacology
|
June 1, 2006
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma
Monica M Mita, Eric K Rowinsky, Leonardo Forero, et al.
The Lancet. Oncology
|
May 29, 2025
Health-related quality of life, pain, and symptomatic skeletal events with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
Karim Fizazi, Michael J Morris, Neal D Shore, et al.
Page
of 43